Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2002 7
2003 9
2004 18
2005 14
2006 16
2007 9
2008 11
2009 14
2010 8
2011 9
2012 17
2013 12
2014 12
2015 12
2016 6
2017 9
2018 11
2019 17
2020 12
2021 3
2022 3
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Kristensen LE, et al. Among authors: yndestad a. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17. Ann Rheum Dis. 2023. PMID: 36931693 Free PMC article. Clinical Trial.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Charles-Schoeman C, et al. Among authors: yndestad a. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22. Ann Rheum Dis. 2023. PMID: 36137735 Free PMC article.
Activin A in nonalcoholic fatty liver disease.
Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P. Yndestad A, et al. Vitam Horm. 2011;85:323-42. doi: 10.1016/B978-0-12-385961-7.00015-9. Vitam Horm. 2011. PMID: 21353887 Review.
Inflammatory cytokines as biomarkers in heart failure.
Ueland T, Gullestad L, Nymo SH, Yndestad A, Aukrust P, Askevold ET. Ueland T, et al. Among authors: yndestad a. Clin Chim Acta. 2015 Mar 30;443:71-7. doi: 10.1016/j.cca.2014.09.001. Epub 2014 Sep 6. Clin Chim Acta. 2015. PMID: 25199849 Review.
A vital role for complement in heart disease.
Lappegård KT, Garred P, Jonasson L, Espevik T, Aukrust P, Yndestad A, Mollnes TE, Hovland A. Lappegård KT, et al. Among authors: yndestad a. Mol Immunol. 2014 Oct;61(2):126-34. doi: 10.1016/j.molimm.2014.06.036. Epub 2014 Jul 16. Mol Immunol. 2014. PMID: 25037633 Free article. Review.
Chemokines and cardiovascular risk.
Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK. Aukrust P, et al. Among authors: yndestad a. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1909-19. doi: 10.1161/ATVBAHA.107.161240. Epub 2008 Jul 31. Arterioscler Thromb Vasc Biol. 2008. PMID: 18669888 Review.
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Dougados M, et al. Among authors: yndestad a. Ann Rheum Dis. 2023 Apr;82(4):575-577. doi: 10.1136/ard-2022-223406. Epub 2023 Jan 31. Ann Rheum Dis. 2023. PMID: 36720582 Free PMC article. No abstract available.
215 results